ByHeart Update: FDA Confirms Review of ByHeart's Root Cause Investigation and Action Plan, Following Completion of Facility Inspections

FDA reported no factors explaining the cause of the botulinum outbreak in ByHeart facilities and closed its review without further questions on ByHeart’s investigation and Action Plan. ByHeart is rolling out new C. botulinum testing protocols that are reportedly 1,000x more sensitive than the standard industry methodology, signaling a heightened compliance and detection push. Net impact appears limited near-term, but the unresolved root-cause finding keeps sentiment cautious.